TABLE 1

Baseline characteristics of CIF-positive and CIF-negative patientsa

CharacteristicCIF positive (n = 101)CIF negative (n = 110)P value
Mean age (yr)33.232.40.60
Female sex (no. [%])49 (48.5)58 (52.7)0.50
F508del/F508del (no. [%])50 (49.5)63 (57.3)0.15
FEV1 (% predicted [mean ± SD])62.3 ± 23.366.1 ± 23.20.23
Pancreatic insufficiency (no. [%])88 (87.1)93 (84.6)0.70
Pseudomonas colonization (no. [%])89 (88.1)88 (80.0)0.14
Treatment (no. [%])
    Inhaled antibioticb82 (81.2)76 (69.1)0.05
    Chronic oral antibioticc28 (27.7)15 (13.6)0.01
    Azithromycin71 (70.3)76 (69.1)0.93
    Antifungald7 (6.9)7 (6.4)0.88
  • a CIF, clinically important fungi defined as Aspergillus, Scedosporium, Trichosporon, and Exophiala species.

  • b Tobramycin powder/solution, aztreonam, colistin, or ceftazidime.

  • c Sulfamethoxazole/trimethoprim, minocycline, doxycycline, or linezolid.

  • d Itraconazole, voriconazole, or posaconazole.